Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Public Health ; 12(6): 873-877, 2019.
Article in English | MEDLINE | ID: mdl-31213410

ABSTRACT

BACKGROUND: Due to the increasing availability of antiretroviral treatment, HIV infected children are living longer which points out the necessity of disclosure. And which is important to support the uptake and adherence to treatment. Disclosure is an important measure to prevent secondary transmission when children are sexually active. OBJECTIVE: The aim of this study was to determine the prevalence of HIV positive status disclosure and associated factors among human immune virus-infected children in pediatric antiretroviral treatment clinics in Gondar town public health facilities. METHOD: An institution based cross-sectional study was conducted among 449 primary caregivers of children aged 6-15years in regular follow-up at pediatric ART clinics in Gondar town public health facilities between March 3, 2018, to April 25, 2018. All subjects in the study area were included in the study. Data was collected in 5 pediatric ART clinics in Gondar town by structured questionnaires through face to face interview and supplemented by chart review to obtain some clinical factors. The variables which have an association with disclosure were identified on the basis of AOR, with 95%CI and p-value <0. 05. Model fitness was checked using Hosmer and Lemeshow goodness of fit test. RESULT: Out of 449 participants, 418 were interviewed with response rate of 93%. The prevalence of HIV positive status disclosure found to be 44%. Age of child >10years [AOR=5.88, (95% CI: 3.52, 9.81)], duration on ART [AOR=2.67 (95% CI: 1.59, 4.51)], place of follow-up [AOR=2.23 (95% CI: 1.27, 5.01)] and educational status of caregiver [AOR=3.00 (95% CI: 1.62, 5.56)] were identified variables. CONCLUSION: The prevalence of disclosure found to be low. Therefore appropriate measure should be taken to promote disclosure.


Subject(s)
Anti-Retroviral Agents/therapeutic use , Disclosure/statistics & numerical data , Disease Transmission, Infectious/prevention & control , HIV Infections/drug therapy , HIV Infections/prevention & control , Secondary Prevention/methods , Adolescent , Child , Cross-Sectional Studies , Ethiopia , Female , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...